The role of the vascular endothelial growth factor (VEGF) in the stimulation of tumor angiogenesis, the maintenance of existing vessels, and the resistance to therapies, along with its negative prognostic significance in non-small cell lung cancer (NSCLC), have made it an important therapeutic target against this tumor [2]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.